269 related articles for article (PubMed ID: 31271486)
61. Phytochemical naphtho[1,2-b] furan-4,5‑dione induced topoisomerase II-mediated DNA damage response in human non-small-cell lung cancer.
Chien CM; Yang JC; Wu PH; Wu CY; Chen GY; Wu YC; Chou CK; Tseng CH; Chen YL; Wang LF; Chiu CC
Phytomedicine; 2019 Feb; 54():109-119. PubMed ID: 30668360
[TBL] [Abstract][Full Text] [Related]
62. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
63. The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.
Smith KA; Cowell IG; Zhang Y; Sondka Z; Austin CA
Genes Chromosomes Cancer; 2014 Feb; 53(2):117-28. PubMed ID: 24327541
[TBL] [Abstract][Full Text] [Related]
64. Topoisomerase II Chromatin Immunoprecipitation.
Smith KA; Cowell IG; Austin CA
Methods Mol Biol; 2018; 1703():183-189. PubMed ID: 29177743
[TBL] [Abstract][Full Text] [Related]
65. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; So S; Koyama H
Biochem Biophys Res Commun; 2004 Jun; 318(4):856-61. PubMed ID: 15147950
[TBL] [Abstract][Full Text] [Related]
66. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
[TBL] [Abstract][Full Text] [Related]
67. Chromatin damage generated by DNA intercalators leads to degradation of RNA Polymerase II.
Espinoza JA; Kanellis DC; Saproo S; Leal K; Martinez JF; Bartek J; Lindström MS
Nucleic Acids Res; 2024 May; 52(8):4151-4166. PubMed ID: 38340348
[TBL] [Abstract][Full Text] [Related]
68. Etoposide, topoisomerase II and cancer.
Baldwin EL; Osheroff N
Curr Med Chem Anticancer Agents; 2005 Jul; 5(4):363-72. PubMed ID: 16101488
[TBL] [Abstract][Full Text] [Related]
69. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
70. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
71. Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.
Atkin ND; Raimer HM; Wang YH
Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31614754
[TBL] [Abstract][Full Text] [Related]
72. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
73. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
74. A flow cytometry-based method for a high-throughput analysis of drug-stabilized topoisomerase II cleavage complexes in human cells.
de Campos-Nebel M; Palmitelli M; González-Cid M
Cytometry A; 2016 Sep; 89(9):852-60. PubMed ID: 27517472
[TBL] [Abstract][Full Text] [Related]
75. Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.
Peter S; Yu H; Ivanyi-Nagy R; Dröge P
Nucleic Acids Res; 2016 Dec; 44(22):e162. PubMed ID: 27587582
[TBL] [Abstract][Full Text] [Related]
76. The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Xiao H; Goodrich DW
Oncogene; 2005 Dec; 24(55):8105-13. PubMed ID: 16091739
[TBL] [Abstract][Full Text] [Related]
77. ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links.
Schellenberg MJ; Lieberman JA; Herrero-Ruiz A; Butler LR; Williams JG; Muñoz-Cabello AM; Mueller GA; London RE; Cortés-Ledesma F; Williams RS
Science; 2017 Sep; 357(6358):1412-1416. PubMed ID: 28912134
[TBL] [Abstract][Full Text] [Related]
78. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
79. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
80. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]